We are specialized in developing novel proprietary psychedelic molecules resulting in more controlled and safer experiences, and no hallucinogenic effects. Our intellectual property is secured.
We have full expertise in drug and clinical development, regulatory affairs and psychedelic-specific manufacturing.
Scientific studies show that certain psychedelic molecules have powerful anti-inflammatory properties. Our proprietary molecules can help control peripheral and central neuroinflammation without hallucinogenic effects.
With our partner, we synthesize new molecules in-house.
Our formulations have improved safety profiles and unique features.
Sintalica Bioscience Corp.
100 King Street West, Toronto, Ontario M5X 2A2, Canada
Copyright © 2022 Sintalica Corp. - All Rights Reserved.